Nathan Sudeep,Noah Kojima,Jeffrey D Klausner
Nathan Sudeep
Background: Nirmatrelvir has been shown to reduce morbidity and mortality associated with COVID-19. However, it is underutilized due to concerns regarding COVID-19 symptom rebound following nirmatrelvir's standard 5-day c...
Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir [0.03%]
从依非韦伦换用依法韦仑/科比司他后胰岛素抵抗增强
Richard Taylor Pickering,Archana Asundi,Alex Olson et al.
Richard Taylor Pickering et al.
Background: Integrase strand transfer inhibitors (INSTIs) have been associated with excess weight gain in people living with HIV compared to other antiretroviral agents. The mechanisms that underlie these effects are not ...
Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study [0.03%]
丹麦莫努匹韦治疗新冠肺炎患者的临床结局——一项全国登记队列研究
Carsten S Larsen,Caroline L Westergaard,Nina B Stærke et al.
Carsten S Larsen et al.
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitali...
Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort [0.03%]
伏立伟抑制剂/恩曲他滨/特诺福韦艾拉酚胺(BIC/FTC/TAF)换药策略对病毒学抑制患者的疗效：单一中心队列的现实世界数据
R A Passerotto,F Lamanna,P F Salvo et al.
R A Passerotto et al.
Introduction: BIC/FTC/TAF showed efficacy and tolerability in randomized trials as a switch strategy in virologically-suppressed people living with HIV. We evaluated its effectiveness in a real-life setting. ...
Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach [0.03%]
基于多阶段计算机模拟的新冠肺炎康复计划：针对主要蛋白酶的FDA批准药物再定位研究
Ahmed M Metwaly,Eslam B Elkaeed,Aisha A Alsfouk et al.
Ahmed M Metwaly et al.
Background: The COVID-19 pandemic has created an urgent need for effective therapeutic agents. The SARS-CoV-2 Main Protease (Mpro) plays a crucial role in viral replication and immune evasion, making it a key target for d...
Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study [0.03%]
儿童水痘脑炎风险因素分析及预测模型构建：队列研究
Ce Wang,Li Tang,Dandan Guo
Ce Wang
Introduction: This study aimed to analyze the risk factors for varicella encephalitis in children and establish a predictive model. Methods: ...
Shahrzad Zangooie,Reza Ghanbari,Farid Azizi Jalilian et al.
Shahrzad Zangooie et al.
Background: This in vitro study aimed to investigate the effect of several phenolic compounds, including doxorubicin, quercetin, and resveratrol, on HSV-1 infection. ...
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study [0.03%]
恩曲他滨搭配阿巴呋伏昔与特诺福韦艾拉酚胺治疗高病毒载量慢性乙型肝炎初始48周疗效和安全性的比较：一项单中心回顾性研究
Qing Zhang,Jianhua Xu,Dan Liu et al.
Qing Zhang et al.
Background/aim: Tenofovir amibufenamide (TMF) employs innovative ProTide technology and a methylation strategy to enhance the lipid solubility and plasma stability of the amide bond, providing advantages over tenofovir al...
Comparative Study
Antiviral therapy. 2024 Oct;29(5):13596535241284226. DOI:10.1177/13596535241284226 2024
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort [0.03%]
与未接受治疗的对照组相比单克隆抗体疗法对轻中度新型冠状病毒肺炎患者临床转归的影响
Courtney N Nichols,Mark Lustberg,Mohammed Mahdee E Sobhanie et al.
Courtney N Nichols et al.
Background: Monoclonal antibody therapy (MAT) received Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for mild to moderate COVID-19 treatment in adults at a high-risk for progression to severe diseas...
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study [0.03%]
andrographolide通过下调ace2表达抑制新冠病毒感染：机制研究
Qing Li,Hongmei Lu,Yongdui Ruan et al.
Qing Li et al.
Angiotensin-converting enzyme 2 (ACE2) is the receptor that enables SARS-CoV-2 to invade host cells. Previous studies have reported that reducing ACE2 expression may have an anti-SARS-CoV-2 effect. In this study, we constructed a pGL4.10-F2...